This review highlights the utility of electrophysiologic testing in symptomatic WPW patients and the growing role of nonpharmacologic therapies like radiofrequency ablation.
Answers are grounded in this paper and cite their sources.
May inform selective testing in symptomatic WPW; leaves open comparative effectiveness of nonpharmacologic therapies.
Though tachyarrhythmias occur commonly in patients with the Wolff-Parkinson-White syndrome, many patients remain asymptomatic. Recent studies suggest that routine electrophysiologic testing in these individuals is of limited value. However, electrophysiologic testing remains very helpful in the symptomatic patient for predicting arrhythmia recurrence and for determining accessory pathway location and function. Unfortunately, noninvasive tests to predict high-risk WPW patients has not been proven helpful because of their low specificity. A number of recent studies have shown that autonomic function can markedly improve accessory pathway function and even counteract the effect of antiarrhythmic drugs. Given the frequent failure of antiarrhythmic therapy in the WPW syndrome, there has been increasing interest in nonpharmacologic therapies, including high-energy DC shock and radiofrequency catheter ablation of accessory pathways, which may prove to be more cost-effective than surgery.
No takes yet. Share an insight, caveat, or question.
Wharton et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: